Rezolute reports FY2023 net loss of $51.8M; Phase 3 for RZ358 to start Q4 2023

Rezolute, Inc.

Cash and equivalents $16.0M, marketable securities $102.3M as of June 30, 2023.
Full year net loss $51.8M vs $41.1M prior year; R&D spend $43.8M (up from $32.5M).
Phase 3 sunRIZE study for RZ358 in congenital HI to initiate Q4 2023; topline data H1 2025.
Phase 2 study of RZ402 for diabetic macular edema ongoing; results expected Q1 2024.
Q4 net loss $12.7M vs $9.4M in prior year quarter.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Rezolute, Inc. reported financial results for the fourth quarter and full fiscal year ended June 30, 2023.

Period: the fourth quarter and full fiscal year ended June 30, 2023
Result: reported results

Exact text from the filing

On September 14, 2023, Rezolute, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Rezolute, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-100787

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.